A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...
Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents ...
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results